Astex Pharmaceuticals to Present at EORTC-NCI-AACR

Astex Pharmaceuticals, Inc. logo

DUBLIN, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of three abstracts for presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Poster presentations will occur Nov 7 – 9 in Dublin, Ireland.

XIAP Abstract #85, Poster Board #052
Poster Presentation: Wednesday, Nov 7, 2012 12:00 – 2:15 pm GMT
Characterization of a potent XIAP and cIAP1 dual antagonist in models of melanoma and leukemia
AT13387 Abstract #293, Poster Board #043
Poster Presentation: Thursday, Nov 8, 2012 12:00 – 2:15 pm GMT
Activity of the HSP90 inhibitor, AT13387, in ALK-driven tumor models
SGI-110 Abstract #465, Poster Board #036
Poster Presentation Friday, Nov 9, 2012 8:30 – 10:30 am GMT
SGI-110, a novel second generation DNA hypomethylating agent, enhances sorafenib activity and alters methylation signature of HCC cell lines

Select posters will be made available for viewing on the company's website following the public presentation.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit

The Astex Pharmaceuticals, Inc. logo is available at

CONTACT: Timothy L. Enns Astex Pharmaceuticals, Inc. Senior Vice President Corporate Communications & Marketing Tel: +1 (925) 560-2810 E-mail: Alan Roemer The Trout Group Managing Director Tel: +1 (646) 378-2945 E-mail: Susanna Chau Astex Pharmaceuticals, Inc. Manager Investor Relations Tel: +1 (925) 560-2845 E-mail: Kari Watson MacDougall Biomedical Communications Senior Vice President Tel: +1 (781) 235-3060 E-mail:

Source:Astex Pharmaceuticals, Inc.